… antiplatelet therapy in cardiovascular disease focusing particularly on the duration of dual
antiplatelet therapy, … platelet function testing, and potential future targets of antiplatelet agents. …

… As this review centres on antiplatelet therapy, we will not discuss the pharmacology of the
… concomitant use of DOACs with antiplatelets for cardiovascular prevention, largely thanks to …

… antiplatelet therapy may find their way into clinical use, although much more study is needed.
… Figure 2 shows various antiplatelet therapies that target receptors on the surface of the …

… Antiplatelet therapy is therefore important for both the treatment and prevention of
cardiovascular disease. Aspirin, the most widely used antiplatelet agent, inhibits platelet cyclo-…

… -drug interactions that might interfere with antiplatelet therapy cardioprotection. Eventually,
it … of antiplatelet therapy to prove efficacy, as is done with anticoagulation therapy with …

… A PAR-1 antagonist added to traditional antiplatelet therapy … benefit/risk balance of antiplatelet
therapy, either by reducing … intensified regimens of antiplatelet therapy will require more …

… with vascular disease. Clinical trials evaluating combination antiplatelet therapies will direct
… and propagation of thrombus formation, antiplatelet drugs have emerged as key agents for …

… Prevention of arterial thrombosis is the primary indication for antiplatelet therapy, and …
novel antiplatelet agents with favorable safety profiles. The results of the Antiplatelet Trialists’ …

… In fact, up to half of patients with AF needing anticoagulation have comorbid coronary
artery disease (CAD), nearly 10% of whom will undergo PCI and need antiplatelet therapy. …

… Recent studies have shown that the addition of cilostazol to dual antiplatelet therapy (triple
antiplatelet therapy) is associated with a reduced risk of stent thrombosis, restenosis and …